Metabolic myopathies: The challenge of new treatments

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 338-345

  Angelini, Corrado ^a   Semplicini, Claudio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE; CREATINE; DIPEPTIDYL CARBOXYPEPTIDASE; GENTAMICIN; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PYRIDOXINE; RAMIPRIL; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SOMATOMEDIN B RECEPTOR; SUCROSE; ANTILIPEMIC AGENT; FATTY ACID;

ANGIONEUROTIC EDEMA; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME REPLACEMENT; EXERCISE; FATTY ACID OXIDATION; GENE EXPRESSION; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DIET; REVIEW; TACHYCARDIA; ADULT; ANIMAL; CHILD; DEFICIENCY; EARLY DIAGNOSIS; ENZYMOLOGY; GENETICS; GLYCOGEN STORAGE DISEASE TYPE II; GLYCOGEN STORAGE DISEASE TYPE V; INFANT; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES;

ADULT; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CARNITINE O-PALMITOYLTRANSFERASE; CHILD; EARLY DIAGNOSIS; ENZYME REPLACEMENT THERAPY; FATTY ACIDS; GLYCOGEN STORAGE DISEASE TYPE II; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; INFANT; OXIDATION-REDUCTION; HYPOLIPIDEMIC AGENTS;

EID: 77954656443     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.02.006     Document Type: Review

References (59)

1. Bembi B., Cerini E., Danesino C., Donati M.A., Gasperini S., Morandi L., Musumeci O., Parenti G., Ravaglia S., Seidita F., et al. Diagnosis of glycogenosis type II. Neurology 2008, 71:S4-S11.
2. Schoser B., Hill V., Raben N. Therapeutic approaches in glycogen storage disease type II (GSDII)/Pompe disease. Neurotherapeutics 2008, 5:569-578.
3. Kishnani P., Steiner R., Bali D., Berger K., Byrne B.J., Case L., Crowley J., Downs S., Howell R.R., Kravitz R.M., et al. Pompe disease diagnosis and management guideline. Genet Med 2006, 8:267-288.
4. Angelini C., Nascimbeni A.C. Late-onset GSDII with novel GAA gene mutation. Clin Genet 2008, 71:374-375.
5. Bembi B., Cerini E., Danesino C., Donati M.A., Gasperini S., Morandi L., Musumeci O., Parenti G., Ravaglia S., Seidita F., et al. Management and treatment of glycogenosis type II. Neurology 2008, 71:S12-S36.
6. Margolis M.L., HowlettP, Goldberg R., Eftychiadis A., Levine S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest 1994, 105:947-949.
7. Laforet P., Nicolino M., Eymard P.B., Pucch J.P. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000, 55:1122-1128.
8. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet 2008, 372:1342-1353.
9. Nascimbeni A.C., Fanin M., Tasca E., Angelini C. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology 2008, 70:617-626.
10. Raben N., Roberts A., Plotz P.H. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007, 26:45-48.
11. Radojevic, Humm A.M., Rösler K.M., Lauterburg T., Burgunder J.-M. Abnormal trafficking of sarcolemmal proteins in α-glucosidase deficiency. Acta Neuropathol 2003, 105:373-380.
12. Hagemans M.L., Hop W.J., Van Doorn P.A., Reuser A.J., Van der Ploeg A.T. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 2006, 66:581-583.
13. Hug G., Schubert W.K. Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger. J Cell Biol 1967, 35:C1-C6.
14. Slonim R.A., Coleman M.A., McElligot J.N., Hirschorn G.U., Ladabie R.M., Mrak R., Evans O.B., Shipp E., Presson R. Improvement of muscle function in acid maltase deficiency by high protein diet. Neurology 1983, 33:34-38.
15. Slonim A.E., Bulone L., Goldberg T., Minikes J., Slonim E., Galanko J., Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35:70-77.
16. McVie-Wylie A.J., Lee K.L., Qiu H., Jin X., Do H., Gotschall R., Thurberg B.L., Rogers C., Raben N., O'Callaghan M., et al. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab 2008, 94:448-455.
17. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001, 3:132-138.
18. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
19. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., Bauer M.S., et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009, 66:329-335.
20. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009, 11:210-219.
21. Kishnani P.S., Goldenberg P.C., Dearmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010, 1:26-33.
22. Winkel L.P., Van den Hout J.M., Kamphoven J.H., Disseldorp J.A., Remmerswaal M., Arts W.F., Loonen M.C., Vulto A.G., Van Doorn P.A., De Jong G., et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004, 55:495-502.
23. Angelini C., Semplicini C., Tonin P., Filosto M., Pegoraro E., Sorarù G., Fanin M. Progress in enzyme replacement therapy in glycogen storage disease type II. Ther Adv Neurol Disord 2009, 2:143-153.
24. Merk T., Wibmer T., Schumann C., Krüger S. Glycogen storage disease type II (Pompe disease)-influence of enzyme replacement therapy in adults. Eur J Neurol 2009, 16:274-277.
25. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010, 257:91-97.
26. Case L.E., Koeberl D.D., Young S.P., Bali D., DeArmey S.M., Mackey J., Kishnani P.S. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 2008, 95:233-235.
27. Pichiecchio A., Poloni G.U., Ravaglia S., Ponzio M., Germani G., Maranzana D., Costa A., Repetto A., Tavazzi E., Danesino C., Moglia A., Bastianello S. Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?. Muscle Nerve 2009, 40:122-125.
28. Okumiya T., Kroos M.A., Vliet L.V., Takeuchi H., Van der Ploeg A.T., Reuser A.J. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 2007, 90:49-57.
29. Parenti G., Zuppaldi A., Gabriela Pittis M., Rosaria Tuzzi M., Annunziata I., Meroni G., Porto C., Donaudy F., Rossi B., Rossi M., et al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 2007, 15:508-514.
30. Flanagan J.J., Rossi B., Tang K., Wu X., Mascioli K., Donaudy F., Tuzzi M.R., Fontana F., Cubellis M.V., Porto C., et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 2009, 30:1683-1692.
31. DiMauro S., Hays A.P., Tsujino S. Nonlysosomal Glycogenosis 2004, 1535-1538. McGraw-Hill Inc., New York. Myology, A.G. Engel, C. Franzini-Armstrong (Eds.).
32. Haller R.G., Vissing J. Spontaneous " second wind" and glucose-induced second " second wind" in McArdle disease: oxidative mechanism. Arch Neurol 2002, 59:1395-1402.
33. Quinlivan R., Vissing J. 144th ENMC International Workshop: outcome measures in McArdle disease, 29 September-1 November 2006, Naarden, The Netherlands. Neuromusc Disord 2007, 17:494-498.
34. Vorgerd M. Therapeutic options in other metabolic myopathies. Neurotherapeutics 2008, 5:579-582.
35. Vissing J., Haller R.G. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003, 349:2503-2509.
36. Andersen S.T., Haller R.G., Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 2008, 65:786-789.
37. Slonim A.E., Goans P.J. Myopathy in McArdle's syndrome. Improvement with a high-protein diet. N Engl J Med 1985, 312:355-359.
38. Vorgerd M., Zange J. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myol 2007, 26:61-63.
39. Busch V., Gempel K., Hack A., Müller K., Vorgerd M., Lochmüller H., Baumeister F.A. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol 2005, 58:341.
40. Andersen S.T., Jeppesen T.D., Taivassolo T., Sveen M., Heincke K., Haller R.G., Vissing J. Effect of changes in fat availability on exercise capacity in McArdle disease. Arch Neurol 2009, 66:762-766.
41. Andersen S.T., Vissing J. Carbohydrate-rich and protein-rich diets in McArdle disease: effect on exercise capacity. J Neurol Neurosurg Psychiatry 2008, 79:1359-1363.
42. Vorgerd M., Zange J., Kley R., Grehl T., Hüsing A., Jäger M., Müller K., Schröder R., Mortier W., Fabian K., et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 2002, 5:97-101.
43. Vorgerd M., Grehl T., Jager M., Muller K., Freitag G., Patzold T., Bruns N., Fabian K., Tegenthoff M., Mortier W., et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000, 57:956-963.
44. Haller R.G., Wyrick P., Taivassalo T., Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 2006, 59:922-928.
45. Gómez-Gallego F., Santiago C., Morán M., Pérez M., Maté-Muñoz J.L., del Valle M.F., Rubio J.C., Garcia-Consuegra I., Foster C., Andreu I.A., et al. The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease. Br J Sports Med 2008, 42:134-140.
46. Rubio J.C., Gómez-Gallego F., Santiago C., García-Consuegra I., Pérez M., Barriopedro M.I., Andreu A.L., Martín M.A., Arenas J., Lucia A. Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 2007, 422:217-222.
47. Martinuzzi A., Liava A., Trevisi E., Antoniazzi L., Frare M. Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor. Acta Myol 2007, 26:64-66.
48. Phoenix J., Hopkins P., Bartram C., Beynon R.J., Quinlivan R.C., Edwards R.H. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. Neuromuscul Disord 1998, 8:210-212.
49. Quinlivan R., Beynon R.J., Martinuzzi A. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database Syst Rev 2008, 16:CD003458.
50. Andreu A.L., Nogales-Gadea G., Cassandrini D., Arenas J., Bruno C. McArdle disease: molecular genetic update. Acta Myol 2007, 26:53-57.
51. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999, 104:375-381.
52. Schroers A., Kley R.A., Stachon A., Horvath R., Lochmüller H., Zange J., Vorgerd M. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 2006, 66:285-286.
53. Siguake E., Rakheja D., Kitson K., Bennet M.J. Carnitine palmitoyl transferase 2 deficiency: a clinical, biochemical, and molecular review. Lab Invest 2003, 83:1543-1554.
54. Ørngreen M.C., Olsen D.B., Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology 2002, 59:1046-1051.
55. Ørngreen M.C., Ejstrup R., Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003, 61:559-561.
56. Djouadi F., Bonnefont J.P., Thuillier L., Droin V., Khadom N., Munnich A., Bastin J. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 2003, 54:446-451.
57. Djouadi F., Aubey F., Schlemmer D., Ruiter J.P., Wanders R.J., Strauss A.W., Bastin J. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 2005, 14:2695-2703.
58. Djouadi F., Aubey F., Schlemmer D., Gobin S., Laforet P., Wanders R.J., Strauss A.W., Bonnefont J.P., Bastin J. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?. J Inherit Metab Dis 2006, 29:341-342.
59. Bonnefont J.P., Bastin J., Behin A., Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009, 360:838-840.